InVivo BioTech Services GmbH of Hennigsdorf at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine

InVivo BioTech Services GmbH

Neuendorfstr. 24 A, 16761 Hennigsdorf
Telephone +49 3302 883769
Fax +49 3302 883771

Hall map

MEDICA 2018 hall map (Hall 3): stand C11

Fairground map

MEDICA 2018 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing

Immuno assay testing

About us

Company details

InVivo BioTech is an ISO 9001 certified CMO with over 20 years of experience in protein production. The company is providing monoclonal antibodies and recombinant proteins for its customers, which include diagnostics companies, major research institutes and biopharmaceutical companies. Its production covers quantities from milligrams to grams of purified antibodies, including all subclasses of IgGs, IgMs and IgEs derived from a collection of more than 3,500 different hybridoma clones producing human, rat or mouse monoclonals. InVivo BioTech uses proprietary media for serum-free cultivation to facilitate highly productive and cost-effective processes in a high cell density fermentation process with yields up to 500 mg of antibody per liter of culture per day. 

InVivo BioTech provides a complete range of biotech services, from cloning, screening and recombinant expression of antigens to the generation of hybridoma cell lines, and from characterization of antibodies to final production of the developed monoclonal antibodies. InVivo BioTech's selection of bacterial, insect and mammalian protein expression systems provides a wide range of choices for various applications, taking into account specific CMO customer needs concerning quantity, bioactivity, structure, post-translational modifications and purity.

Recombinant proteins are produced via transient transfection.  InVivo’s Expression System for transient Transfection is a high yielding expression platform meeting the demands of early and late stage drug discovery and development approaches.


More Less